Oral Contraceptive Rx-to-OTC Switch On The Cusp In UK
The MHRA is consulting on two Rx-to-OTC switch applications for progestogen-only contraceptive pills containing desogestrel, one from HRA Pharma and one from Maxwellia. The move has been welcomed by UK consumer healthcare industry association, the PAGB, as well as the British Pregnancy Advisory Service.
You may also be interested in...
Sanofi's Nasacort Allergy Relief hay fever spray is the latest in a flood of reclassifications in the UK since the beginning of the year when the country left the European Union.
Maxwellia is ready to market its Lovima daily contraceptive as a non-prescription brand if its application to switch the progestogen-only pill (POP) in the UK is approved, representing a leap forward for the company. CEO Anna Maxwell tells HBW Insight about Maxwellia's journey from R&D start-up to consumer health player.
On International Women's Day, we post an update from HRA Pharma, which has appointed Brands2Life to promote the firm's Hana daily contraceptive as a non-prescription medicine in the UK, should the Rx-to-OTC switch currently under consideration be successful.